Cohen R, Raymond J, Faye A, Gillet Y, Grimprel E
GPIP, 27, rue Inkermann, 94100 Saint-Maur, France; Unité court séjour, petits nourrissons, service de néonatologie, UPEC, université Paris XII, CHI de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
GPIP, 27, rue Inkermann, 94100 Saint-Maur, France; Service de bactériologie, université Paris-Descartes, hôpital Cochin, 2, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
Arch Pediatr. 2015 Jun;22(6):665-71. doi: 10.1016/j.arcped.2015.03.016. Epub 2015 Apr 28.
Urine dipsticks have to be used more frequently for the screening of urinary tract infections (UTI) in febrile infants and children (grade A). Confirmation of the UTI by urine culture should prefer other methods of sampling than the urine bag: sampling jet, urethral catheterization, or pubic puncture (grade A). The percentage of Escherichia coli producing extended-spectrum beta-lactamases (ESBL) in children accounts for less than 10 % in France and does not justify revising the 2007 recommendations (grade B). An increase in the use of carbapenems in first-line treatment is a major environmental hazard and exposes the patient to the risk of untreatable infections. For febrile UTI, the expert group recommended: (1) recover the results of susceptibility testing as soon as possible to quickly adapt treatment for possible resistant strains; (2) favor initial treatment with aminoglycosides (particularly amikacin) which remain active in the majority of ESBL strains for patients seen in the pediatric emergency department and/or hospital; (3) ceftriaxone (IV or IM) remains an appropriate treatment for patients seen in the emergency department or outpatient clinic because the percentage of ESBL-producing enterobacteria strains remains low; (4) use oral cefixime (grade B) in nonsevere cases and low-risk patients defined as age>3 months, general condition preserved, disease duration of fever<4 days, no associated comorbidity, and no history of urinary tract infection, uropathy, or prior antibiotic therapy in the last 3 months; (5) oral relay for parenteral treatment is guided by in vitro susceptibility testing, in an attempt to reduce the use of oral cephalosporins to limit the selection of resistant bacterial strains. The total duration of treatment recommended is usually 10 days. Except for special circumstances, there is no need to prescribe retrograde cystography or antibiotic prophylaxis after a first febrile urinary tract infection. For cystitis, the panel recommends systematic urinalysis and initial prescription before the results of the urine culture of one of the three following oral antibiotics: amoxicillin-clavulanate, cotrimoxazole, cefixime. The total duration of antibiotic treatment is 5days to tailor treatment based on clinical progression and antibiotic susceptibility.
对于发热婴幼儿和儿童,必须更频繁地使用尿试纸筛查尿路感染(UTI)(A级)。通过尿培养确诊UTI时,采样方法应优先选择除尿袋外的其他方法:采样喷射法、尿道插管法或耻骨穿刺法(A级)。在法国,儿童中产超广谱β-内酰胺酶(ESBL)的大肠杆菌百分比低于10%,因此没有理由修订2007年的建议(B级)。在一线治疗中增加碳青霉烯类药物的使用是一个重大的环境危害,会使患者面临无法治疗的感染风险。对于发热性UTI,专家组建议:(1)尽快获取药敏试验结果,以便迅速调整治疗方案以应对可能的耐药菌株;(2)对于在儿科急诊科和/或医院就诊的患者,首选氨基糖苷类药物(尤其是阿米卡星)进行初始治疗,这类药物对大多数ESBL菌株仍有活性;(3)头孢曲松(静脉注射或肌肉注射)仍是急诊科或门诊患者的合适治疗药物,因为产ESBL的肠杆菌菌株百分比仍然较低;(4)对于年龄>3个月、一般状况良好、发热病程<4天、无合并症且在过去3个月内无尿路感染、泌尿系统疾病或先前抗生素治疗史的非重症和低风险患者,使用口服头孢克肟(B级);(5)根据体外药敏试验指导肠外治疗转为口服治疗,以减少口服头孢菌素的使用,从而限制耐药菌株的选择。推荐的总治疗疗程通常为10天。除特殊情况外,首次发热性尿路感染后无需进行逆行膀胱造影或预防性使用抗生素。对于膀胱炎,专家组建议在尿培养结果出来之前,系统地进行尿液分析并初始开具以下三种口服抗生素之一:阿莫西林-克拉维酸、复方新诺明、头孢克肟。抗生素治疗的总疗程为5天,根据临床进展和抗生素敏感性调整治疗方案。